Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects.
We analyzed retrospectively, by use of logistic regression, the role of the phenotypic susceptibility score (PSS) as a determinant of virologic outcome in a study of treatment-experienced human immunodeficiency virus (HIV) type 1-infected subjects. A model for PSS in which each drug was treated equally and scored as active or inactive was not predictive of HIV-1 RNA load (VL) suppression. However, weighting the potential contribution of each drug on the basis of inferred potency and by use of a continuous scale to quantify drug susceptibility revealed significant associations between PSS and outcome. Entry VL was a strong independent predictor of therapy outcome, and PSS was a strong predictor of the magnitude of the initial decrease in VL. This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment.
University of North Carolina Center for AIDS Research, University of North Carolina, Chapel Hill 27599, USA. risunc@med.unc.edu
Ronald
R
Swanstrom
Ronald J
RJ
Bosch
David
D
Katzenstein
Hailong
H
Cheng
Hongyu
H
Jiang
Nicholas
N
Hellmann
Richard
R
Haubrich
Susan A
SA
Fiscus
Courtney V
CV
Fletcher
Edward P
EP
Acosta
Roy M
RM
Gulick
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D010641:Phenotype; D011237:Predictive Value of Tests; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors